N
ROIV icon

Natixis’s Roivant Sciences ROIV Stock Holding History

Natixis’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Sell
9,867
-2,933
-23% -$86.7K ﹤0.01% 886
2026
Q1 		$355K Buy
+12,800
New +$329K ﹤0.01% 861
2024
Q4 		– Sell
-68
Closed -$785 – 1170
2024
Q3 		$785 Buy
+68
New +$774 ﹤0.01% 913

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Natixis's ROIV Position: Q2 2026 in Review

Natixis reduced its Roivant Sciences (ROIV) stake by 23% in Q2 2026, selling an estimated $86.7K and leaving 9,867 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Natixis first reported a position in ROIV in Q3 2024 and has held it in 3 quarters since. The position peaked at $355K in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Natixis held 9,867 shares of Roivant Sciences worth $349K as of Q2 2026.
  • Natixis sold 2,933 Roivant Sciences shares in Q2 2026, an estimated $86.7K.
  • Roivant Sciences made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #886 holding.
  • Natixis first reported a position in Roivant Sciences in Q3 2024 and has held it in 3 quarters since.
  • Natixis's Roivant Sciences position peaked at $355K in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.